Filing Flows

Filing Flows › Usana Health Sciences (USNA) › Q2 2025

Usana Health Sciences (USNA) Q2 2025 earnings results (second quarter 2025)

10-Q filed Aug 5, 2025

Usana Health Sciences (USNA) reported revenue of $236M for the second quarter 2025 (Q2 2025), +11% from a year earlier and -5% from the quarter before. Operating margin was 7.1%, net earnings $9.7M (4.1% of revenue).

Revenue$236M
Year over year+11%
Quarter over quarter-5%
Operating margin7.1%
Net earnings$9.7M

Usana Health Sciences, Q2 2025: revenue $236M (+11% year over year), operating margin 7.1%, net earnings $9.7M, operating cash flow $12.2M. The chart follows the revenue to costs, profit and cash.

Q2 2025AmountQ/QY/Y
Revenue$236M-5%+11%
Gross profit$186M-6%+8%
Operating profit$16.7M+7%-6%
Net earnings$9.7M+3%-7%
Operating cash flow$12.2M-21%+53%
Free cash flow$7.2M-43%+35%

What changed

Revenue was $235.8M in Q2 2025, up 11% year over year and down 5% from the previous quarter.

Gross margin was 78.7%, down 2.3 points from a year earlier. Operating profit was $16.7M, a 7.1% margin (down 1.3 points year over year). Operating profit fell $1.1M even though revenue rose $23.0M versus a year earlier, so costs grew faster than sales. Operating expenses grew 9% against revenue growth of 11%. The fastest-growing cost line was SG&A (+27%). Net earnings were $9.7M, down 7% year over year. The effective tax rate was 44.5%.

Operating cash flow was $12.2M (up 53% year over year), 117% of net income including minority interests. Non-cash charges added back $7.7M of depreciation and amortization and $3.6M of share-based compensation. Working capital and other items used $9.6M. Capital expenditures of $5.0M left free cash flow of $7.2M.

Questions

What was Usana Health Sciences' revenue in the second quarter 2025?

Usana Health Sciences (USNA) reported revenue of $236M for the second quarter 2025 (Q2 2025), +11% from a year earlier and -5% from the quarter before.

Was Usana Health Sciences profitable in the second quarter 2025?

Operating profit was $16.7M (7.1% of revenue) and net earnings $9.7M.

Open the interactive Sankey →

Source: Usana Health Sciences 10-Q on SEC EDGAR.